{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:47:00Z","timestamp":1772902020717,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jdiacomp.2015.10.013","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T22:45:53Z","timestamp":1445726753000},"page":"1-2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["The EMPA-REG study: What has it told us? A diabetologist\u2019s perspective"],"prefix":"10.1016","volume":"30","author":[{"given":"Ralph A.","family":"DeFronzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2015.10.013_bb0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocrine Reviews"},{"issue":"13","key":"10.1016\/j.jdiacomp.2015.10.013_bb0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"29","author":"Cherney","year":"2014","journal-title":"Cardiovascular Diabetology"},{"issue":"Suppl. 1","key":"10.1016\/j.jdiacomp.2015.10.013_bb0070","first-page":"A298","article-title":"Improved left ventricular diastolic function (LVDF) following pioglitazone therapy is strongly related to increased myocardial insulin sensitivity","volume":"63","author":"Clarke","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2015.10.013_bb0065","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2015.10.013_bb0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"NEJM"},{"issue":"Suppl. 2","key":"10.1016\/j.jdiacomp.2015.10.013_bb0075","first-page":"S1627","article-title":"In vivo actions of peroxisome proliferator-activated receptors: Glycemic control, insulin sensitivity and insulin secretion","volume":"36","author":"Eldor","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jdiacomp.2015.10.013_bb0060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2015.10.013_bb0030","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"NEJM"},{"key":"10.1016\/j.jdiacomp.2015.10.013_bb0025","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"NEJM"},{"key":"10.1016\/j.jdiacomp.2015.10.013_bb0035","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"NEJM"},{"key":"10.1016\/j.jdiacomp.2015.10.013_bb0015","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.10.013_bb0080","doi-asserted-by":"crossref","first-page":"46","DOI":"10.15277\/bjdvd.2015.021","article-title":"Rehabilitation of pioglitazone","volume":"15","author":"Ryder","year":"2015","journal-title":"The British Journal of Diabetes & Vascular Disease"},{"key":"10.1016\/j.jdiacomp.2015.10.013_bb0020","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2015.10.013_bb0045","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","article-title":"Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study","volume":"113","author":"Williams","year":"2006","journal-title":"Circulation"},{"issue":"9438","key":"10.1016\/j.jdiacomp.2015.10.013_bb0050","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case\u2013control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2015.10.013_bb0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","author":"Zinman","year":"2015","journal-title":"NEJM"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872715004031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872715004031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T06:23:29Z","timestamp":1537251809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872715004031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1056872715004031"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2015.10.013","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The EMPA-REG study: What has it told us? A diabetologist\u2019s perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2015.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}